When talking about later life, the biggest wish for most people is not how long they live, but to remain physically agile and free from the burden of illness. Even many people who exercise regularly regard "aging slowly and passing away peacefully" as their ultimate goal, unwilling to spend their later years bedridden with chronic diseases.
This state that people refer to is what we commonly call "extending healthspan" in the medical field.
The Fried Frailty Phenotype includes 5 components[2]:
- Unintentional weight loss: >3 kg body weight loss in the past 6 months (not due to dieting or exercise)
- Low grip strength: <26 kg for men, <18 kg for women
- Fatigue: Feeling that everything is difficult or lacking energy for more than 3 days in the past week
- Slow gait speed: Timed Up and Go Test (TUGT) >10 seconds
- Low physical activity: Weekly physical activity <600 MET-minutes
Scoring method: 1 point for "yes", 0 points for "no". 0 points = no frailty, 1-2 points = pre-frailty, ≥3 points = frailty.
Landmark Clinical Study Published in Top Journal, Rigorous Design Ensures Reliable Results
In March 2026, Cell Stem Cell, the leading journal in the stem cell field, published a clinical study on stem cell therapy for age-related frailty.
This is a randomized, double-blind, placebo-controlled, dose-escalation phase IIb trial, ranking among the largest and most rigorous studies in the field. A total of 148 participants aged 70 to 85 with mild to moderate frailty were enrolled.
The researchers randomly assigned the participants to 5 groups: 4 stem cell treatment groups and 1 placebo control group.
Participants in the treatment groups received a single intravenous infusion of the stem cell preparation Laromestrocel, with infusion doses of 25 million, 50 million, 100 million, and 200 million cells for the four groups respectively.
All these stem cells were derived from donated bone marrow of healthy adults aged 18 to 45, and were produced through rigorous screening and standardized culture and expansion processes.
The primary outcome measures included the 6-minute walk test, Clinical Frailty Scale ratings, and changes in relevant blood biomarkers.
Remarkable Core Efficacy: Single Infusion Delivers 3x Clinical Standard Endurance Improvement at 9 Months
For frail older adults, a 20-30 meter improvement in 6-minute walk distance is considered a clinically meaningful improvement, and the elderly will noticeably feel better physical condition.
The results of this study far exceeded this basic efficacy standard.
At 9 months after infusion, participants who received the high dose of 200 million cells walked an average of 63.4 meters more in the 6-minute walk test than those in the placebo control group.
This improvement is 3 times the clinical efficacy standard, with a very prominent effect.
Participants who received the 50 million cell dose also walked an average of 49.2 meters more than the control group, also achieving a significant improvement.
In contrast, the average 6-minute walk distance of the elderly in the placebo control group showed a continuous downward trend during the 9-month follow-up period.
The researchers also assessed the overall health status of the elderly using the Clinical Frailty Scale. The results showed that less than 15% of the elderly in the placebo group experienced an improvement in their frailty status.
Among the participants who received stem cell therapy, 30.8% showed a positive improvement in their overall health grade.
Objective Limitations: Specializes in Endurance Repair, No Significant Improvement in Strength and Explosive Power
This stem cell therapy is not a panacea, and the study results clearly demonstrated its limitations.
It showed outstanding efficacy in improving endurance-related physical functions, but there was no statistically significant improvement in explosive power tests or muscle strength tests.
However, this limitation does not affect the core clinical value of this therapy.
For frail older adults, basic daily activities such as walking, grocery shopping, and climbing stairs all rely on endurance-related physical functions.
Improvements in this area can already substantially enhance their quality of life and reduce the risk of disability.
Reference
[2] Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.